Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy (2019)
- Authors:
- Autor USP: ROCHA, VANDERSON GERALDO - FM
- Unidade: FM
- DOI: 10.1182/bloodadvances.2019000627
- Subjects: TRANSPLANTE HOMÓLOGO; LINFÓCITOS T; LEUCEMIA MIELOIDE AGUDA; DOENÇAS DA MEDULA ÓSSEA; DOENÇA ENXERTO-HOSPEDEIRO; FÁRMACOS IMUNOSSUPRESSORES; CONDICIONAMENTO; SOBREVIVÊNCIA LIVRE DE DOENÇA; ESTUDOS RETROSPECTIVOS
- Agências de fomento:
- Financiado pelo ONR
- Health Resources and Services Administration (US Department of Health and Human Services)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [HHSH250201200016C]
- National Institute of Allergy and Infectious Diseases, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [5U24-CA076518]
- National Heart, Lung, and Blood Institute, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U24-CA076518, 5U10HL069294]
- National Cancer Institute, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5U24-CA076518, 5U10HL069294]
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2019
- Source:
- Título: Blood advances
- ISSN: 2473-9529
- Volume/Número/Paginação/Ano: v. 3, n. 19, p. 2836-2844, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SOLOMON, Scott R et al. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood advances, v. 3, n. 19, p. 2836-2844, 2019Tradução . . Disponível em: https://doi.org/10.1182/bloodadvances.2019000627. Acesso em: 24 fev. 2026. -
APA
Solomon, S. R., Martin, A. S., Shah, N. N., Fatobene, G., Malki, M. M. A., Ballen, K. K., et al. (2019). Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood advances, 3( 19), 2836-2844. doi:10.1182/bloodadvances.2019000627 -
NLM
Solomon SR, Martin AS, Shah NN, Fatobene G, Malki MMA, Ballen KK, Bashey A, Bejanyan N, Meade JB, Rocha VG. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy [Internet]. Blood advances. 2019 ; 3( 19): 2836-2844.[citado 2026 fev. 24 ] Available from: https://doi.org/10.1182/bloodadvances.2019000627 -
Vancouver
Solomon SR, Martin AS, Shah NN, Fatobene G, Malki MMA, Ballen KK, Bashey A, Bejanyan N, Meade JB, Rocha VG. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy [Internet]. Blood advances. 2019 ; 3( 19): 2836-2844.[citado 2026 fev. 24 ] Available from: https://doi.org/10.1182/bloodadvances.2019000627 - Comparison of characteristics and laboratory tests of COVID-19 hematological patients from France and Brazil during the pre-vaccination period: identification of prognostic profiles for survival
- Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe
- Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases
- A novel mutation in RHAG causing Rh-null phenotype in Colombia. [Editorial]
- Comparative analysis of the variability of the human leukocyte antigen peptide-binding pockets in patients with acute leukaemia
- Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan
- Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
- Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era
- Validation of a formula predictive of peripheral blood stem cell yield and successful collection in healthy allogeneic donors
- Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease [Carta]
Informações sobre o DOI: 10.1182/bloodadvances.2019000627 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
